» Articles » PMID: 16672397

In Vitro Release by Aspergillus Fumigatus of Galactofuranose Antigens, 1,3-beta-D-glucan, and DNA, Surrogate Markers Used for Diagnosis of Invasive Aspergillosis

Overview
Specialty Microbiology
Date 2006 May 5
PMID 16672397
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Aspergillus markers are becoming increasingly important for the early diagnosis of invasive aspergillosis. The kinetics of release of these surrogate markers, however, is largely unknown. We investigated the release of beta-(1-5)-galactofuranosyl (galf) antigens (Platelia Aspergillus), 1,3-beta-D-glucan (BG) (Fungitell), and DNA (PCR) in an in vitro model of Aspergillus fumigatus. The results showed that release is correlated to the growth phase of the fungus, which depends on available nutrients. Whereas galf antigens and BG are released during logarithmic growth, DNA is released only after mycelium breakdown. During early logarithmic growth, galf antigens seem to be released somewhat earlier than BG. Furthermore, galf antigen concentrations of more than 120,000 times the serum cutoff value (0.5 ng/ml) can be measured, while BG concentrations reach a value only 978 times the serum cutoff value (60 pg/ml). During lytical growth, release of galf antigens further increased to a maximum level, which depended on pH. After that, the concentration of galf antigens stayed high (pH 7.4) or decreased to zero within 4 days (pH 5.0). In contrast to galf antigens, BG concentration decreased after 1 day of growth. The decrease of galf components seems to be due to the enzyme beta-galactofuranosidase, which is able to destroy galf epitopes and whose activity fluctuates in the culture filtrates in parallel with galf antigen concentration. Fungal DNA seems to be released only due to autolysis caused by nutrient limitation. In conclusion, several factors clearly influence the release of surrogate markers in vitro. These same factors might also play a role at the infection site of Aspergillus disease in humans.

Citing Articles

Fatal invasive pulmonary aspergillosis in an immunocompetent patient with COVID-19 due to : A case study.

Abolghasemi S, Hakamifard A, Sharifynia S, Pourabdollah Toutkaboni M, Tehrani H Clin Case Rep. 2021; 9(4):2414-2418.

PMID: 33936706 PMC: 8077262. DOI: 10.1002/ccr3.4051.


Performance, Correlation and Kinetic Profile of Circulating Serum Fungal Biomarkers of Invasive Aspergillosis in High-Risk Patients with Hematologic Malignancies.

Siopi M, Karakatsanis S, Roumpakis C, Korantanis K, Eldeik E, Sambatakou H J Fungi (Basel). 2021; 7(3).

PMID: 33805751 PMC: 7999040. DOI: 10.3390/jof7030211.


(1→3)-β-D-glucan testing for the detection of invasive fungal infections in immunocompromised or critically ill people.

White S, Schmidt R, Walker B, Hanson K Cochrane Database Syst Rev. 2020; 7:CD009833.

PMID: 32693433 PMC: 7387835. DOI: 10.1002/14651858.CD009833.pub2.


Galactofuranose-Related Enzymes: Challenges and Hopes.

Senicar M, Lafite P, Eliseeva S, Petoud S, Landemarre L, Daniellou R Int J Mol Sci. 2020; 21(10).

PMID: 32423053 PMC: 7278926. DOI: 10.3390/ijms21103465.


Hypoxia Decreases Diagnostic Biomarkers for Aspergillosis In Vitro.

Maurer E, Aigner M, Lass-Florl C, Binder U J Fungi (Basel). 2019; 5(3).

PMID: 31336719 PMC: 6787614. DOI: 10.3390/jof5030061.


References
1.
Cousin M, Notermans S, Hoogerhout P, VAN Boom J . Detection of beta-galactofuranosidase production by Penicillium and Aspergillus species using 4-nitrophenyl beta-D-galactofuranoside. J Appl Bacteriol. 1989; 66(4):311-7. DOI: 10.1111/j.1365-2672.1989.tb02484.x. View

2.
Steinbach W, Stevens D, Denning D, Moss R . Advances against aspergillosis. Clin Infect Dis. 2003; 37 Suppl 3:S155-6. DOI: 10.1086/376522. View

3.
Challier S, Boyer S, Abachin E, Berche P . Development of a serum-based Taqman real-time PCR assay for diagnosis of invasive aspergillosis. J Clin Microbiol. 2004; 42(2):844-6. PMC: 344496. DOI: 10.1128/JCM.42.2.844-846.2004. View

4.
Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M . Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001; 97(6):1604-10. DOI: 10.1182/blood.v97.6.1604. View

5.
Reiss E, Obayashi T, Orle K, Yoshida M, Zancope-Oliveira R . Non-culture based diagnostic tests for mycotic infections. Med Mycol. 2001; 38 Suppl 1:147-59. View